Zhang Lin, Zeng Juan, Zhu Wenying, Sha Jing, Tang Yue, Leng Bing, Guo Nan, Jiang Jinjiao
Department of Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.
Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.
Infect Drug Resist. 2025 Sep 4;18:4731-4739. doi: 10.2147/IDR.S538120. eCollection 2025.
To investigate the impact of varying renal function on serum sulbactam concentrations and antibiotic efficacy in critically ill patients with hospital-acquired pneumonia (HAP) who exhibit no elevation in serum creatinine levels.
A prospective observational study was conducted on 23 adult HAP patients in the ICU of Shandong Provincial Hospital who received intravenous cefoperazone/sulbactam, from January 2021 to January 2023. Renal function was estimated using serum creatinine (eGFRcreat) and cystatin C (eGFRcys). An eGFRcreat >130 mL/min or eGFRcys >80 mL/min indicated augmented renal clearance. Serum sulbactam levels were measured at 0 min (pre-dose) and 15, 30, 60, 120, 180, 360, and 480 min after the >6th dose using HPLC-MS/MS.
Among all the 23 patients, 10 had an eGFRcreat above 130 mL/min and 9 had an eGFRcys above 80 mL/min. Additionally, 13 patients exhibited an eGFRcreat ranging from 47 to 123 mL/min, and 14 patients had an eGFRcys in the range of 22 to 75 mL/min. In patients with higher estimated glomerular filtration rate (eGFR), regardless of whether it was based on creatinine or cystatin C, the serum sulbactam concentration tend to decrease more rapidly after the end of administration. Patients with higher eGFR also tend to have a shorter half time and lower drug exposure (AUC). Five patients experienced antibiotic treatment failure. The median eGFRcreat and eGFRcys of these 5 patients were both higher than those patients who responded positively to antibiotic therapy, although not statistically significant.
Patients with higher eGFR demonstrated decreased levels of sulbactam. Despite the discrepancy in GFR estimated by creatinine and cystatin C, both the two biomarkers yielded similar predictions of variability in serum sulbactam concentration. Currently, there is no evidence in this study indicating that differences in renal function affect treatment outcomes in critically ill patients without elevated creatinine levels. Further research is warranted to explore the influence of varying renal function-related pharmacokinetic fluctuations on antibiotic efficacy.
探讨肾功能变化对血清肌酐水平未升高的医院获得性肺炎(HAP)重症患者血清舒巴坦浓度及抗生素疗效的影响。
2021年1月至2023年1月,对山东省立医院重症监护病房(ICU)的23例接受静脉注射头孢哌酮/舒巴坦的成年HAP患者进行了一项前瞻性观察研究。使用血清肌酐(eGFRcreat)和胱抑素C(eGFRcys)评估肾功能。eGFRcreat>130 mL/min或eGFRcys>80 mL/min表明肾脏清除率增加。在第6剂之后的0分钟(给药前)以及第15、30、60、120、180、360和480分钟,使用高效液相色谱-串联质谱法(HPLC-MS/MS)测量血清舒巴坦水平。
在所有23例患者中,10例eGFRcreat高于130 mL/min,9例eGFRcys高于80 mL/min。此外,13例患者的eGFRcreat在47至123 mL/min之间,14例患者的eGFRcys在22至75 mL/min之间。在估计肾小球滤过率(eGFR)较高的患者中,无论其基于肌酐还是胱抑素C,给药结束后血清舒巴坦浓度往往下降得更快。eGFR较高的患者半衰期也往往较短,药物暴露量(AUC)较低。5例患者抗生素治疗失败。这5例患者的eGFRcreat和eGFRcys中位数均高于对抗生素治疗反应阳性的患者,尽管差异无统计学意义。
eGFR较高的患者舒巴坦水平降低。尽管肌酐和胱抑素C估计的肾小球滤过率存在差异,但这两种生物标志物对血清舒巴坦浓度变异性的预测相似。目前,本研究中没有证据表明肾功能差异会影响肌酐水平未升高的重症患者的治疗结果。有必要进一步研究探讨肾功能相关药代动力学波动对抗生素疗效的影响。